Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Lung Neoplasms 8Carcinoma, Non-Small-Cell Lung 6Breast Neoplasms 6Sarcoma 5Unspecified Adult Solid Tumor, Protocol Specific 4Neoplasm Metastasis 4Colorectal Neoplasms 4Neoplasms 3Melanoma 3Colonic Neoplasms 3Thymoma 2Rectal Neoplasms 2Primary Myelofibrosis 2Pancreatic Neoplasms 2Myeloproliferative Disorders 2Multiple Myeloma 2Mesothelioma, Malignant 2Leukemia, Myelomonocytic, Chronic 2Esophageal Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Thrombocythemia, Essential 1Solid Tumor, Adult 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Recurrence 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1

Interventions

ruxolitinib 5Filgrastim 4Decitabine 4Cyclophosphamide 4fludarabine phosphate 3Peripheral Blood Stem Cell Transplantation 3Methylprednisolone 3Etoposide 3Topotecan 2Tacrolimus 2Prednisone 2LY2784544 2Cytarabine 2Cyclosporine 2Carboplatin 2Antilymphocyte Serum 2veliparib 1tipifarnib 1talazoparib 1spartalizumab 1sonidegib 1sargramostim 1sabatolimab 1romidepsin 1pyroxamide 1poly ICLC 1peginterferon alfa-2a 1nelarabine 1navitoclax 1arsenous acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Thrombocythemia, Essential × Celecoxib × Clear all
NCT04041050 2025-02-14

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

AbbVie

Phase 1 Active not recruiting
85 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Neoplasms, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡